Journal: Antibiotics

Article Title: Distinct Effectiveness of Oritavancin against Tolerance-Induced Staphylococcus aureus

doi: 10.3390/antibiotics9110789

Figure Lengend Snippet: Activity of study antibiotics against mupirocin-induced tolerant staphylococci. Data represent the mean and standard deviation values from five distinct strains, each evaluated in triplicate. Dashed lines, uninduced control; open circles, low mupirocin induction (0.032 µg/mL); gray diamonds, moderate mupirocin induction (0.32 µg/mL); black squares, high mupirocin induction (3.2 µg/mL). Antibiotic abbreviations are as follows: CPT, ceftaroline; DAL, dalbavancin; DAP, daptomycin; ORI, oritavancin; TLV, telavancin; VAN, vancomycin. Uninduced and low-induction exposures were not significantly different at any time point with the exception of CPT and VAN where the two exposures each differed at 48 h ( p < 0.01). Moderate and high mupirocin induction were essentially indistinguishable from each other and significantly different from uninduced strains ( p < 0.01) at all time points and for all exposures with the exception of ORI ( p > 0.05).

Article Snippet: Antibiotics were supplemented at static concentrations corresponding to the estimated free serum concentration following standard dosing including ceftaroline (CPT, Allergan, Madison, NJ, USA, 17 mg/L), dalbavancin (DAL, Durata Therapeutics, Chicago, IL, USA, 6 mg/L), daptomycin (DAP, Mylan, Canonsburg, PA, USA, 6 mg/L), oritavancin (ORI, Melinta, New Haven CT, USA, 14 mg/L), telavancin (TLV, Theravance Biopharma, San Francisco, CA, USA, 10 mg/L) and vancomycin (VAN, Mylan, New Haven, CT, USA, 35 mg/L).

Techniques: Activity Assay, Standard Deviation, Control